Taisho Pharma (TAISF) 105.0000 $TAISF Attention Deficit

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Taisho Pharma (TAISF) 105.0000 $TAISF

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.00 (+0.22), MDGN: 5.81 (+0.16), ADHD: 5.00 (+0.09), SUPN: 23.35 (+0.62), COLL: 10.65 (-1.09), DRRX: 1.81 (+0.01), NEOS: 7.27 (-1.30), NDRM: 17.92 (-0.24), MRK: 63.63 (+0.99), SHPG: 198.42 (-0.32), ITCI: 40.72 (-0.53)

Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8tvk9/mycoplasma) has announced the addition of the "Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" provides an overview of Mycoplasma Pneumoniae Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycoplasma Pneumoniae Infections. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Cempra, Inc. - KYORIN Holdings, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Shenzhen Kexing Biotech Co., Ltd. - Pfizer Inc. - Fujifilm Holdings Corporation - Daiichi Sankyo Company, Limited For more information visit http://www.researchandmarkets.com/research/z8tvk9/mycoplasma
PFE: 35.20 (+0.05), CEMP: 23.56 (+0.79)

Acute Upper Respiratory Tract Infections Global Clinical Trials Review Report, H2, 2015 - Analysis & Opportunities
M2 - Fri Dec 11, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8gxbss/acute_upper) has announced the addition of the "Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" provides an overview of Acute Upper Respiratory Tract Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Upper Respiratory Tract Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - NPF Materia Medica Holding - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Rose Pharmed Biotechnology Co. - Reckitt Benckiser Group Plc - Novartis AG - Laboratoires Pierre Fabre SA - Daewon Pharm Co. Ltd. For more information visit http://www.researchandmarkets.com/research/8g...cute_upper
VRX.TO: 31.76 (-3.99), NVS: 82.21 (-0.59)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 0

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Balavant Insurance Group Welcomes John Jankowski as CIO

Updated Category News Views 317

Leadership Appointment at Balavant Insurance Group Balavant Insurance Group has made a significant move by appointing John Jankowski as its new Chief Information Officer. This announcement marks a pivotal moment for the company, known for its focus on technological advancement and innovative insurance solutions. Strategic Role of the Chief Information Officer In his role,...

Continue Reading
Exploring the Growth of the Industrial Absorbent Sector

Updated Category News Views 245

Understanding the Industrial Absorbent Market Dynamics The industrial absorbent market is poised for remarkable growth, expected to reach $5.50 billion by 2031. This growth trajectory aligns with a compound annual growth rate (CAGR) of 4.3%. The increase in market size is largely driven by the rising usage of absorbents across various industries in response to...

Continue Reading
ChoiceOne Financial Services Achieves Successful Bank Merger

Updated Category News Views 147

Successful Bank Merger by ChoiceOne Financial Services ChoiceOne Financial Services, Inc. (NASDAQ: COFS), the parent company of ChoiceOne Bank, has achieved a significant milestone by completing the consolidation of The State Bank into ChoiceOne Bank. This strategic move empowers the strength of ChoiceOne, further enhancing its service capabilities and market presence. A...

Continue Reading
Danantara Indonesia and INA Forge Nickel Investment Alliance with Eramet

Updated Category News Views 443

Strategic Collaboration for Nickel Development In a significant move to bolster the nickel downstream industry, partners including Danantara Indonesia and the Indonesia Investment Authority (INA) have officially signed a Memorandum of Understanding (MoU) with the prominent French mining company, Eramet. This collaboration aims to create an extensive investment platform...

Continue Reading
Full Moon Bar-B-Que's Generous Initiative for Local Kids

Updated Category News Views 180

Full Moon Bar-B-Que's Generosity In a heartwarming gesture, Full Moon Bar-B-Que has made a significant impact on the community by contributing $200,000 worth of backpacks and school supplies. Their ongoing commitment through the Backpack Blessings program is not just about donations; it's about nurturing and empowering local children who need support the most. Supporting...

Continue Reading